Divya Vijendra, MD
Medical Oncology · Bryan, OHNPI 1164502373
Payments from drug & device makers
Across 89 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$207
- Genentech USA, Inc.$152
- Merck$138
- Jazz Pharmaceuticals Inc.$125
- Daiichi Sankyo Inc.$124
- Johnson & Johnson$122
- plus $1K from 29 others
What the payments were for
- Food & beverage$1,80991%
- Education$1789%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $207 |
| Genentech USA, Inc. | 5 | $152 |
| Merck | 7 | $138 |
| Jazz Pharmaceuticals Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 6 | $124 |
| Johnson & Johnson | 7 | $122 |
| Pfizer | 6 | $121 |
| Beigene USA, Inc. | 4 | $116 |
| Amgen | 5 | $108 |
| Pinnacle Biologics, Inc | 2 | $97 |
| Bristol Myers Squibb | 4 | $78 |
| Agios Pharmaceuticals, Inc. | 3 | $58 |
| AstraZeneca(2 entities) | 3 | $46 |
| Sanofi | 2 | $46 |
| Incyte Corporation | 2 | $36 |
| AbbVie | 1 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Dova Pharmaceuticals | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $21 |
| Tesaro, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$125
How this compares
$1,987 in reported general payments places this provider in the 25th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 19 | $246 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Bryan
- Michael WangBelpre$21.6M
- Kai HeColumbus$10.9M
- Timothy BurnsColumbus$7.2M
- Dwight OwenColumbus$6.8M
- Jennifer SelfridgeCleveland$6.3M
- Moshe OrnsteinCleveland$6.1M
- David CarboneColumbus$5.4M
- Manisha ShahColumbus$4.3M
- Gregory OttersonColumbus$4.1M
- Marcelo BonomiColumbus$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.